Literature DB >> 27847927

Family association study of Transforming Growth Factor Beta1 gene polymorphisms in schizophrenia.

Paweł Kapelski1, Maria Skibińska1, Małgorzata Maciukiewicz2, Dorota Zaremba1, Maria Jasiak3, Joanna Hauser1.   

Abstract

OBJECTIVES: Schizophrenia is a serious mental illness with chronic symptoms and significant impairment in psychosocial functioning. An etiopathological role for immunologic abnormalities in schizophrenia was hypothesized. Inflammatory markers are well-known etiological factors for psychiatric disorders, including schizophrenia. Several studies have investigated the possible effects of antipsychotics on inflammation and neurogenesis. Additionally, antiinflammatory adjuvant therapy has been under investigation as a treatment option for schizophrenia. Transforming Growth Factor Beta 1 (TGFB1) signaling is critical for many biological processes, including proliferation, development, differentiation and regeneration. Multiple members of the TGFB1 superfamily play a role in the developing nervous system and are regulated by neuronal activity. We conducted family-based study to assess whether TGFB1 gene is associated with susceptibility to schizophrenia in Polish population.
METHODS: Two functional polymorphisms: rs1800469 (C-509T) and rs1800470 (T869C) of TGFB1 gene were analyzed within a group of 147 trios (patients diagnosed with schizophrenia and their healthy parents) using Transmission Disequilibrium Test (TDT).
RESULTS: No association of these polymorphisms with schizophrenia was found in Polish population.
CONCLUSIONS: Further studies on larger groups along with correlation with circulating protein levels are needed.

Entities:  

Keywords:  Transforming Growth Factor Beta 1; polymorphism; schizophrenia

Mesh:

Substances:

Year:  2016        PMID: 27847927     DOI: 10.12740/PP/61273

Source DB:  PubMed          Journal:  Psychiatr Pol        ISSN: 0033-2674            Impact factor:   1.657


  2 in total

1.  Integrating eQTL data with GWAS summary statistics in pathway-based analysis with application to schizophrenia.

Authors:  Chong Wu; Wei Pan
Journal:  Genet Epidemiol       Date:  2018-02-07       Impact factor: 2.135

2.  The use of pharmacogenetic testing in patients with schizophrenia or bipolar disorder: A systematic review.

Authors:  Melanie Routhieaux; Jessica Keels; Erika E Tillery
Journal:  Ment Health Clin       Date:  2018-11-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.